02 9487 9111
The University of Sydney Avondale College of Higher Education

Sydney Adventist Hospital
« View pages

Clinical Specialties - Cancer

Clinical Trials Unit Publications


Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.

Hovey E, de Souza P, Marx G, Parente P, Rapke T, Hill A, Bonaventura A, Michele A, Craft P, Abdi E, Lloyd A; on behalf of the MOTIF investigators.
Support Care Cancer. 2013 Dec 17. [Epub ahead of print]
PMID: 24337761 [PubMed - as supplied by publisher]
Related citations
Select item 24043751


Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C.

J Clin Oncol. 2013 Oct 20;31(30):3800-6. doi: 10.1200/JCO.2012.44.6716. Epub 2013 Sep 16.
PMID: 24043751 [PubMed - indexed for MEDLINE]
Related citations
Select item 23984777


Severe symptomatic hypocalcaemia following a single dose of denosumab.

McLachlan JM, Marx GM, Bridgman M.

Med J Aust. 2013 Aug 19;199(4):242-3. No abstract available.
PMID: 23984777 [PubMed - indexed for MEDLINE]
Related citations
Select item 23975226


Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.
PMID: 23975226 [PubMed - in process]
Related citations
Select item 23879909


Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer.

Won AC, Gurney H, Marx G, De Souza P, Patel MI.

BJU Int. 2013 Aug;112(4):E250-5. doi: 10.1111/bju.12169.
PMID: 23879909 [PubMed - indexed for MEDLINE]
Related citations


1: Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators.

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

Eur J Cancer. 2013 Nov;49(17):3648-57. doi:10.1016/j.ejca.2013.07.144. Epub 2013 Aug 22. PubMed PMID: 23973186.

2: Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators.

Alpha emitter radium-223 and survival in metastatic prostate cancer.

N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. PubMed PMID: 23863050.

3: Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators.

Abiraterone in metastatic prostate cancer without previous chemotherapy.

N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584. PubMed PMID: 23228172; PubMed Central PMCID: PMC3683570.

4: Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R;

Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804. PubMed PMID: 23219286; PubMed Central PMCID: PMC3596060.

5: Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Lancet Oncol. 2012 Oct;13(10):983-92. doi:10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. PubMed PMID: 22995653.

6: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

JAMA. 2012 Jul 11;308(2):147-56. doi: 10.1001/jama.2012.7352. Erratum in: JAMA. 2012 Nov 14;308(18):1861. PubMed PMID: 22782416.



von Moos R, et al. Effect of Skeletal-related Events on Pain Interference in Patients With Solid Tumors and Bone Metastases. Eur J Cancer 2013;49(suppl 2; abstr 1306). [ECC]


Fallowfield L, et al. Impact of skeletal-related events on pain and analgesic use in patients with solid tumors and bone metastases. J Clin Oncol 31, 2013 (suppl; abstr e20514). [ASCO]


Fallowfield L, et al. Pain progression and analgesic use in patients with solid tumors and bone metastases with skeletal-related events. Support Care Cancer (2013) 21 (Suppl 1):S1–S301 (abstr 0334) [MASCC]



Lisa Horvath, Hui-Ming Lin, Lesley Castillo, Kate Lynette Mahon, Karen Chiam, Brian Yong Lee, Quoc Nguyen, Wenjia Qu, Michael J. Boyer, Martin R. Stockler, Nick Pavlakis, Gavin M. Marx, Girish Mallesara Hiriyanna Gowda, Howard Gurney, Susan J. Clark, Alex Swarbrick, Roger J. Daly.

Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer. J Clin Oncol 32, 2014 (suppl 4; abstr 44)


Kate Lynette Mahon, Wenjia Qu, James Devaney, Cheryl Paul, Lesley Castillo, Richard Wykes, Mark D Chatfield, Michael J. Boyer, Martin R. Stockler, Gavin M. Marx, Howard Gurney, Girish Mallesara Hiriyanna Gowda, Peter Molloy, Lisa Horvath, Susan J. Clark.

Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC). J Clin Oncol 32, 2014 (suppl 4; abstr 11)


Donald Patrick, Charles Cleeland, Lesley Fallowfield, Matthew Smith, Laurence Klotz, Stephane Oudard Gavin Marx, Rachel Wei, Katarina Ohrling, Yi Qian. ASCO GU January 2014.

Denosumab or Zoledronic Acid Therapy on Pain Interference and Cancer-Specific Quality of Life in Patients with Castrate-resistant Prostate Cancer and Bone Metastases. J Clin Oncol 32, 2014 (suppl 4; abstr 12)

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services